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Abstract: Low maternal vitamin D levels during pregnancy have been linked to various 
health outcomes in the offspring, ranging from periconceptional effects to diseases of adult 
onset. Maternal and infant cord 25(OH)D levels are highly correlated. Here, we review the 
available evidence for these adverse health effects. Most of the evidence has arisen from 
observational epidemiological studies, but randomized controlled trials are now underway. 
The evidence to date supports that women should be monitored and treated for vitamin D 
deficiency during pregnancy but optimal and upper limit serum 25(OH)D levels during 
pregnancy are not known. 
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1. Review  
The high prevalence of vitamin D insufficiency during pregnancy is increasingly recognized, amid 
growing evidence that the intrauterine environment can have both immediate and long-lasting effects 
on health of the offspring. In this review, we outline the research evidence to date relating to vitamin D 
status and pregnancy, including a range of possible health outcomes from pre-conception to later life 
(Figure 1). With regard to terminology, we use vitamin D when referring to cholecalciferol or 
ergocalciferol (but ‘vitamin D3’ or ‘vitamin D2’ where reference is made specifically to only a single 
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form of calciferol); 25(OH)D to refer to 25 hydroxycalciferol (including both 25(OH)D2 and 
25(OH)D3), and 1,25(OH)2D, the active form of the hormone, to include both 1,25(OH)2D2  and 
1,25(OH)2D3.  
Figure 1. Manifestation of reviewed possible major outcomes related to vitamin D status at 
different life stages. 
 
2. Synthesis and Action of 1,25(OH)2D  
Human exposure to the UV-B wavelengths of ultraviolet radiation (UVR) results in molecular 
instability in a cholesterol precursor (7-dehydrocholesterol) present in the skin, with the formation of 
previtamin D3. Still within the skin, previtamin D3 undergoes a chemical rearrangement to form 
vitamin D3 (cholecalciferol) that is taken up into the circulation largely bound to the vitamin D binding 
protein [1]. Vitamin D may also be consumed as part of the diet and/or in supplements [2] with the 
relative proportions deriving from diet or synthesis variable by location and culture. Dietary vitamin D 
may be in the form of vitamin D2 (ergocalciferol), derived from plants, or vitamin D3, sourced from 
fatty fish such as salmon, sardines and mackerel and, to a certain extent, egg yolks [3].  
Both sunlight-derived (vitamin D3) or ingested (vitamin D2 or vitamin D3) vitamin D are transported 
to the liver where 25-hydroxylase enzymes catalyze conversion to the primary storage form (and the 
usual serum measure of vitamin D status), 25-hydroxyvitamin D (25(OH)D) [4]. Conversion to the 
active form of the hormone requires a further hydroxylation, primarily in the kidney, under the control 
of a 1-hydroxylase, forming 1, 25-dihydroxyvitamin D (1,25(OH)2D) [4]. This step is under tight 
feedback control that is dependant on the body’s calcium requirements. It is now clear that a wide 
range of tissues possess the 1-hydroxylase enzyme, so that local conversion of 25(OH)D to the active 
1,25(OH)2D [5] may occur. The active hormone is best known for its role in maintaining serum 
calcium levels in conjunction with parathyroid hormone (PTH). 1,25(OH)2D increases intestinal Nutrients  2009, 1                                       
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calcium absorption [6], thereby suppressing PTH secretion [5] and promoting mineralization (and 
decreasing de-mineralization) of the skeleton [7].  
2.1. Non-calcitropic Actions  
It is now clear that 1,25(OH)2D also has a range of non-calcitropic functions, with locally 
synthesized hormone acting through both paracrine and autocrine signaling [8]. 1,25(OH)2D has been 
shown to stimulate insulin production [9] and thyroid stimulating hormone secretion [10] and improve 
myocardial contractility [11]. 
1,25(OH)2D is an important immunomodulator [12], potentiating antimicrobial peptide 
(cathelicidin) activity in human monocytes [13,14], and strengthening innate immunity. There are also 
effects on adaptive immune function, with attenuation of T lymphocyte proliferation and antigen 
specific activation [15]. Other potential immunoregulative functions are extensive and reviewed 
elsewhere [12]. 
An important role for 1,25(OH)2D in increasing differentiation and suppressing proliferation of 
monocytes was reported in 1981 [16], and was followed by work that showed that 1,25(OH)2D could 
retard cancer cell growth and improve differentiation [17]. Fetal development is perhaps the period of 
greatest differentiation and proliferation: any 1,25(OH)2D effects occurring during this time could have 
wide-ranging consequences. The evidence for some such effects is reviewed in later sections.  
3. Physiology 
Extra calcium is required for fetal growth during pregnancy. The majority of this comes from the 
maternal diet and enhanced intestinal absorption, resulting in a total of around 25–30 g of calcium 
being transferred to the fetus during the pregnancy, mainly in the last trimester [18,19]. Maternal total 
serum calcium levels decline as the pregnancy progresses [20], but during the third trimester the fetus 
maintains higher serum calcium levels (reviewed in [21]) as a result of active transport of the mineral 
across the placenta.  
Maternal 25(OH)D levels do not vary markedly during the pregnancy unless intake or synthesis 
changes [22]. However, serum 1,25(OH)2D concentrations increase 50–100% above the non-pregnant 
state during the second trimester and by 100% during the third trimester [23], largely accounting for 
the increased intestinal absorption of dietary calcium [18].  
25(OH)D crosses the placental barrier [19] and, at birth, cord blood 25(OH)D levels are directly 
correlated with maternal levels [24,25]. Fetal 1,25(OH)2D appears to be largely synthesized in the fetal 
kidney [19,20], possibly with some contribution from placenta-derived 1,25(OH)2D. Indeed, the 
placenta does contain 1α-hydroxylase [20,26], but whether this is mainly required for maintenance of 
adequate local 1,25(OH)2D levels in relation to immune tolerance (including successful implantation 
and maintenance of the pregnancy [26,27]) is not clear. 
4. The Prevalence of Low Vitamin D Status during Pregnancy 
As noted above, vitamin D adequacy depends on both endogenous, UV-induced synthesis, and 
exogenous sources, i.e., diet and supplements. Vitamin D synthesis depends firstly on the level of 
ambient UV-B, with this in turn depending on latitude and altitude, time of the year and time of the Nutrients  2009, 1                                       
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day [28]. For any UV-B level, vitamin D synthesis is then dependent on the amount of skin exposed, 
skin pigmentation, use of sun protection such as shade, sunscreen and possibly other physical or host-
related factors [29,30]. As for other population groups, pregnant women living at high latitude and low 
altitude, with dark skin pigmentation or skin usually covered by clothing will be at increased risk of 
vitamin D deficiency [31,32], unless dietary intake is high (Table 1). Furthermore, since 25(OH)D is 
stored in adipose tissue, there is some evidence that obesity is a further risk factor for vitamin D 
insufficiency. 
Table 1. Risk factors for vitamin D deficiency. 
Low ambient UVR level   High latitude location 
Winter season 
Inadequate sun exposure  Built or indoor environment 
  Extensive clothing cover (e.g., veiled) 
  Excess sun avoidance – (shade, sunscreen) 
Host factors  Dark skin pigmentation 
  Old age 
  Obesity 
  Malabsorptive syndromes (e.g., inflammatory bowel disease) 
 
Many studies have reported on the vitamin D status of pregnant women, in a range of environments 
(summarized in Table 2, including studies from 1997–2006). As expected, vitamin D deficiency is 
particularly common in darkly pigmented mothers, particularly among those who have migrated to 
regions with lower ambient UVR than their evolutionary heritage. Nevertheless, low vitamin D status 
is also prevalent in pregnant Caucasian populations, particularly those not receiving supplementation 
(Table 2). 
Table 2. The prevalence of a low vitamin D status in pregnancy. 
Reference Year  Country  Population  Stage  of 
Pregnancy 
Definition %  n/N 
[127]  1997  Iran  Iran women attending 
largest Tehran hospital 
Delivery  <25 nmol/L  80% (40/50) 
[128] 1997-2001  USA African  American–90% 
receiving prenatal vitamins 
4-21 week gestation  <37.5 nmol/L  44.9% (89/194) 
[128] 1997-2001  USA White–90%  receiving 
prenatal vitamins 
4-21 week gestation  <37.5 nmol/L  2% (4/199) 
[128] 1997-2001  USA African–American  37-42  weeks  <37.5 nmol/L  29.2% (54/185) 
[128]  1997-2001  USA  White  37-42 weeks  <37.5 nmol/L  5% (10/199) 
[128]  1997-2001  USA  Turkish  12 week gestation  <25 nmol/L  83.5% (66/79) 
[128]  1997-2001  USA  Moroccan  12 week gestation  <25 nmol/L  81.2% (56/69) 
[128]  1997-2001  USA  Other non-western  12 week gestation  <25 nmol/L  59% (62/105) 
[129]  1999  Ireland  Caucasians in Ulster–on 
supplements (54–55 
oN) 
12 weeks  <25 nmol/L  4.5% (1/22) 
[129] 1999  Ireland  No  supplements  12  weeks  <25 nmol/L  44.2% (34/77) 
[129] 1999  Ireland  Supplements  20  weeks  <25 nmol/L  22.7% (5/22) Nutrients  2009, 1                                       
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Table 2. Cont. 
[129] 1999  Ireland  No  supplements  20  weeks  <25 nmol/L  50.6% (39/77) 
[129] 1999  Ireland  Supplements  35  weeks  <25 nmol/L  0% (0/22) 
[129] 1999  Ireland  No  supplements  35  weeks  <25 nmol/L  20.8% (16/77) 
[32]  1999-2000  Australia  Veiled &/or dark skinned 
women attending antenatal 
clinic 
During antenatal 
care, when a routine 
blood test was 
ordered 
<22.5 nmol/L  80.5% (66/82) 
[130] 1999-2000  United  Arab 
Emirates 
Kuwait  Delivery  <25 nmol/L  40% (86/214) 
[131]  2002  India  Attendees of Queen Mary’s 
Hosptal, Lucknow (26.8 
oN) 
Northern India – urban 
Delivery–full term, 
live 
<22.5 nmol/L  84.3% 
(118/140) 
[131]  2002  India  Attendees of Queen Mary’s 
Hosptal, Lucknow (26.8 
oN) 
Northern India–urban 
Rural <56.3  nmol/L  84% 
(56/67) 
[132]  2005-2006  India  Residents of Barabanki 
district, 26.8 
oN 
Second trimester  <50 nmol/L  74.1% 
(103/139) 
4.1. Vitamin D Supplementation 
In most countries, the routine monitoring of serum 25(OH)D levels during pregnancy does not 
occur. A 2009 review has recommended that women with one or more risk factors for low serum 
25(OH)D (Table 1) should be monitored at the beginning of gestation and in mid pregnancy [22].  
A number of studies within non-pregnant adult populations have examined 25(OH)D levels in 
relation to different dosages, preparations or dosing intervals of oral vitamin D (reviewed in[33]). 
Recent recommendations suggest that the lower level of vitamin D adequacy should be a serum 
25(OH)D level of 75–80 nmol/L. While there is no clear upper safe limit, a recent review suggested 
that the optimal 25(OH)D level was between 75–110 nmol/L and that these levels could be maintained 
with supplementation of 1,800 to 4,000 IU daily of vitamin D3 [34]. Few studies to date have examined 
vitamin D supplementation during pregnancy, and optimal 25(OH)D levels have not yet been   
defined [35,36]. A daily dose of 1000 IU/day does not appear to be sufficient to achieve and maintain 
vitamin D adequacy in women who are vitamin D deficient at the start of pregnancy [37,38]. Doses of 
over 2000 IU may be needed to achieve levels over 80 nmol/L [39,40] and RCTs are currently 
underway to evaluate this issue. In a recent trial of over 600 pregnant women, 400 IU and 4000 IU of 
vitamin D3 daily were administered [41] and the formal publication of this report is awaited. Among 
non-pregnant women, studies have similarly shown that even high doses of vitamin D3  
(10,000 IU/day) are not usually associated with hypercalcaemia or other toxicity [42-44]. A recent 
meta-analysis of vitamin D supplementation in relation to bone health in adults, showed that for every 
1 IU increase in oral vitamin D3, the 25(OH)D level could be expected to increase by 0.016 nmol/L, 
with a relatively linear relationship at least up to 2000 IU/day [45]. 
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5. Vitamin D Status during Pregnancy and the Effects on Offspring Health over the Life Course 
5.1. Fetal Life 
5.1.1. Conception 
Some older studies showed that vitamin D deficient rats had reduced fertility and litter size, 
associated with impaired ovarian function and spermatogenesis. The latter appeared to be calcium 
modulated and could be reversed with administration of calcium [46]. Sperm count and motility were 
both shown to be reduced and histological abnormalities of the testis were observed in another animal 
model, VDR null mutant mice [47]. However, the association between vitamin D deficiency and 
defective reproduction may be the result of hypocalcaemia rather than a vitamin D effect per se, as the 
infertile female VDR null mice developed normal fertility when fed a calcium rich diet [48]. 
In human in vitro fertilization (IVF) studies, women who achieved a clinical pregnancy had 
significantly higher follicular fluid (Fol F) levels of 25(OH)D than women with unsuccessful   
cycles [49]. Multiple regression analysis confirmed that Fol F 25(OH)D was associated with a 
successful IVF cycle, after adjusting for maternal age, body mass index, ethnicity and number of 
embryos transferred (p = 0.01); for each 2.5 nmol/L increase of Fol F 25(OH)D the likelihood of 
achieving a clinical pregnancy increased by 7% [49]. The authors suggested that higher Fol F 
25(OH)D levels may enhance endometrial receptivity and implantation [49]. 
5.1.2. Immunity 
1,25(OH)2D has effects on immune function within both the innate and adaptive immune systems. 
For example, 1,25(OH)2D regulates the production of the antimicrobial protein cathelicidin, CAMP 
(LL37), an intracellular antimicrobial protein found within lysosomes of neutrophils, macrophages and 
also within trophoblasts [14,50]. Cathelicidin is a key element of innate immunity protecting against 
viral and bacterial infection. During pregnancy, a key requirement for the maternal immune system is 
the development of immune tolerance to the fetus. Recent work further suggests that 1,25(OH)2D may 
be important to specific aspects of placental function [51]. Within the placenta, 1,25(OH)2D can 
function as an intracrine regulator of CAMP (LL37) in trophoblasts, and may thus provide a novel 
mechanism for activation of innate immune responses in the placenta, assisting the pregnancy. 
1,25(OH)2D down-regulates IL-6 production [52] and there is some evidence that adverse 
neurodevelopmental outcomes following maternal infections are mediated by this cytokine [53]. 
Ongoing research is examining the role of 1,25(OH)2D in decreasing the risk  of infections during 
pregnancy and whether vitamin D status alters the risk of developing adverse outcomes following  
such infections.  
5.1.3. Bone formation 
In animal models (mainly rodents), vitamin D–deficient and –insufficient animals appear to have 
normal skeletal mineral content [54]. However, it is not clear that the vitamin D requirements of these 
largely nocturnal animals reflect human needs. Human studies are needed as inter-species variation in 
vitamin D requirements and metabolism may occur [55]. Among vitamin D deficient pregnant women, Nutrients  2009, 1                                       
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fetal ultrasound revealed splaying of the distal metaphysis of the fetal femur as early as 19 weeks, with 
the appearance being very similar to that seen in childhood (vitamin D-deficient) rickets [56]. There 
was a positive correlation between the maternal 25(OH)D level and the fetal metaphyseal cross-
sectional area, with the latter 5% and 14% greater in fetuses of mothers who were vitamin D 
insufficient (serum 25(OH)D 25-50 nmol/L) and vitamin D deficient (serum 25(OH)D < 25 nmol/L) 
compared to vitamin D sufficient mothers (serum 25(OH)D > 50 nmol/L) [56]. There was, however, 
no association between maternal 25(OH)D level and fetal femur length at 19 weeks or 34 weeks 
gestation [56].  
5.2. Perinatal Period 
5.2.1. Immunomodulation 
Early life immunomodulation is likely to also be affected by vitamin D status. At birth, cord serum 
25(OH)D levels are directly correlated with levels of IL-10, an immunosuppressive cytokine [57]. In 
vitro studies show that 1,25(OH)2D acts on naïve T cells to retard their development into either T 
helper 1 or 2 cells [58].  
5.2.2. Mode of Birth 
Recent data suggest an association between vitamin D deficiency and caesarean section. In a cross 
sectional study, caesarean section was almost four-times more common in women with vitamin D 
insufficiency (serum 25(OH)D < 37.5 nmol/L) compared to vitamin D-sufficient women (serum 
25(OH)D ≥ 37.5 nmol/L), after adjustment for race, age, education level, insurance status, and alcohol 
use (Adjusted OR 3.84; 95% CI 1.71–8.62) [59]. 
5.2.3. Birth Weight 
Observational studies of vitamin D status during pregnancy and physical characteristics of the 
offspring are few and provide conflicting results. One study found pregnancies of mothers with low 
vitamin D status were shorter (by 0.7 week; 95% CI −1.3, −0.1) [60], and the babies had poorer 
intrauterine long bone growth [60], while in other studies, offspring had lower birth weight [61-63]. 
However another study found the opposite, with babies of vitamin D deficient mothers being both 
heavier and longer, compared to the offspring of vitamin D-sufficient mothers [64]. Further 
examination of these findings suggests that the effects may vary according to the VDR genotype of the 
offspring. Thus within the offspring of vitamin D deficient mothers, there was lower birth weight in 
those having the FF or Ff genotype (where the F allele is associated with increased vitamin D receptor 
activity [65]), but not in offspring with the ff genotype (P-value for interaction after adjustment for 
potential confounding factors = 0.02) [66]. A large randomized controlled trial on this issue has been 
completed in South Carolina, USA, with recent presentation at the 14th International Vitamin D 
meeting, Brugges, Belgium, in October 2009 [67]. The media reported on a reduction in both preterm 
birth and small-for-dates babies, with vitamin D supplementation [41], but formal publication of the 
findings had not occurred at the time of writing this review, thus these reports cannot be   
formally evaluated.  Nutrients  2009, 1                                       
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5.2.4. Birth Defects 
At this stage, all findings arise from animal studies, primarily in rats, and it is not clear whether 
there is a direct translation to human fetal outcomes. However, there is evidence that 1,25(OH)2D 
regulates cell differentiation and proliferation so that effects on organ development during fetal life are 
plausible and warrant further investigation. In rats, maternal vitamin D deficiency was associated with 
an increase in nephron number, but lower renal corpuscle size [68]. Low maternal vitamin D status 
may slow neonatal cardiac development [69] and alter brain morphology [70, 71], with changes in the 
latter persisting into adulthood [72]. 
Excess vitamin D administration during pregnancy could also potentially be of concern. Rats 
receiving very high-dose vitamin D during gestation and early development (considerably higher than 
would be administered to humans) had adverse changes in elastin content and organization in the aorta 
consistent with increased later risk of hypertension or aneurysm [73]. Nevertheless, in two studies in 
pigs, vitamin D administration to two sows at doses that achieved serum 25(OH)D levels, 
approximating recommended human levels, was associated with coronary lesions in offspring at six 
weeks [74,75]. The relevance of these findings to humans remains to be determined. In 2008, a cohort 
study investigating these issues reported no statistically significant associations between antenatal 
maternal 25(OH)D levels and cardiac measures in offspring at nine years, including in blood pressure, 
carotid intima-media thickness, arterial compliance and cardiac structure [62]. 
5.3. Childhood and Adulthood 
5.3.1. Bone Health 
Maternal vitamin D status influences bone health in the offspring [76]. In a UK cohort study, 
winter-born babies had lower bone mineral content (BMC) than those born in summer [77] and 
maternal serum 25(OH)D in late pregnancy was directly associated with total and lumbar spine BMC 
in offspring at nine years of age [77,78].  
5.3.2. Postnatal Infection 
An increased risk of acute lower respiratory tract infection (ALRI) in newborn infants was 
associated with lower maternal 25(OH)D levels in a case-control study in Turkey [79], but there was 
no association between postnatal serum 25(OH)D levels and infant ALRI in a case-control study in 
Canadian children aged 1–25 months [80]. In a prospective study in Tanzania, children born to 
mothers with lower 25(OH)D levels at 12–27 weeks gestation, had a 46% (95% CI 11%–91%) 
increased risk of contracting HIV infection by 24 months of age, including postnatally during 
breastfeeding, and a 61% higher risk of dying (95% CI 25%–107%) [81]. 
5.3.3. Immune diseases 
Increased risk for a winter season-of-birth is seen in some autoimmune disorders, such as Crohn’s 
disease [82] and type 1 diabetes [83-85], although the latter finding may be limited to comparisons 
within homogeneous populations [86], or in those with specific susceptibility genotypes [87].  Nutrients  2009, 1                                       
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The Diabetes Autoimmunity Study in the Young (DAISY) cohort has observed that maternal intake 
of vitamin D via food, recorded at birth, was significantly associated with a decreased risk of islet 
autoimmunity in offspring during the first four years of life [88]. A Norwegian case control study 
found cod liver oil use during pregnancy was associated with lower risk of type 1 diabetes in the 
offspring, indicating vitamin D or the n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid 
in the cod liver oil, or both, may have a protective effect against type I diabetes [89]. These findings 
are also consistent with the finding of an inverse association between postnatal vitamin D 
supplementation in early life and type 1 diabetes risk [90,91].  
Low vitamin D intake during pregnancy has been associated with an increased risk of asthma, 
eczema or hay fever [92,93], while winter birth was associated with higher IgE levels and lower IL-10 
than summer birth [57]. As IL-10 is important in the development of tolerance to exogenous antigens 
and inhibition of mast cell degranulation [57], these findings are consistent with the notion of low 
vitamin D levels at birth increasing the risk of an allergic propensity. However, the ecological patterns 
are not consistent with this because some studies show a higher prevalence of asthma in warmer 
climates with higher ambient UVR than other locations [94-97]. These regional patterns are not 
necessarily conflicting, because they may also reflect uncontrolled confounding, in that higher house 
dust mite allergen levels may occur in warmer climates. A birth cohort has reported an increase in 
eczema and asthma among children whose mothers had higher 25(OH)D levels during late pregnancy 
(>75 versus <30 nmol/L) [62]. Randomized controlled trial data are required but not yet available. 
5.3.4. Central nervous system disorders 
Vitamin D is a potent inducer of nerve growth factor synthesis [98]. Genes of the vitamin D 
pathway (25 hydroxylase, 1 hydroxylase and 24 hydroxylase) and VDR are expressed in rat brain 
cells [99] and the distribution of VDR and 1 hydroxylase is thought to be similar in rat and human 
brains [100]. In experimental studies, rats deprived of vitamin D prenatally had enlarged lateral 
ventricles, decreased cortical thickness and heavier and longer brains, and altered patterns of   
apoptosis [70,71].  
Seasonal and population level patterns of schizophrenia incidence indicate the possible role of low 
intrauterine vitamin D in increasing later schizophrenia risk. This is a difficult but important area to 
research [101-104], with animal work indicting transient prenatal vitamin D deficiency is associated 
with subtle alterations in learning and memory functions in adult rats [105]. In a Finnish birth cohort 
study, regular vitamin D supplementation (maternal self-report) during the first year of offspring life 
was associated with a reduced risk of schizophrenia in males (but not females) (RR = 0.08, 95% CI 
0.01–0.95) [106].  
Observational studies provide indirect evidence that low vitamin D status during early life may 
increase the risk of multiple sclerosis [107,108]. These findings include a striking season-of-birth 
pattern in a large cohort of Northern Hemisphere MS cases [109], a congruent pattern in the Southern 
hemisphere [110], and a maternal parent-of-origin effect [111,112]. Using prenatal ambient UVR 
levels as an instrumental variable for vitamin D levels in pregnancy [113], an inverse association 
between maternal ambient UVR exposure during the late first trimester and MS risk was   
observed [110]. This inverse association was independent of region of birth, indicating that the first Nutrients  2009, 1                                       
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trimester ambient UVR level was not acting merely as a marker of longer term UVR exposure due to 
region of residence [110].  
5.3.5. Other candidate diseases that require further research with regard to the potential role of prenatal 
vitamin D status. 
Seasonal patterns of birth in adults [114] and children [115] with brain tumors and epilepsy [116] 
have been noted and could be evidence of an effect of low vitamin D status, but this is far from 
conclusive. A tentative link between vitamin D status and autism has been postulated, arising mainly 
from the findings of population level studies [117,118]. Further, adult body mass index and obesity 
prevalence has been noted to vary as a function of month of birth [119,120]. In adult ecological and 
observational studies there is considerable evidence that vitamin D status may be related to risk or 
prognosis of a number of cancers, including of the prostate [121] and breast [122]. One animal study 
has shown that maternal antenatal vitamin D supplementation was associated with greater mean 
prostatic weight and a histologically more differentiated prostatic architecture in offspring in   
adulthood [123]. Whether such changes also occur in humans and have relevance for later prostate 
cancer risk is unknown.  
6. Overview 
In summary, we have reviewed the existing evidence for a range of possible adverse offspring 
health outcomes resulting from low maternal vitamin D status in pregnancy. At this point in time, the 
evidence is largely based on studies of observational rather than experimental design. Insufficient trials 
have occurred for vitamin D supplementation in relation to specific clinical outcomes. Even with these 
trials (mostly of high risk women, many years ago) being systematically reviewed, it appears that there 
is not enough evidence to evaluate the effects of vitamin D supplementation in pregnancy [124]. The 
findings from recent randomized controlled trials [67] are eagerly awaited. The merit of achieving a 
relatively high vitamin D status (>100 nmol/L) has not been fully established, particularly in relation to 
offspring cardiovascular or atopic disease development. However, the majority of potential adverse 
offspring health outcomes pertain to low prenatal vitamin D status and the evolving evidence has 
provided greater impetus for public health efforts to ensure mothers are not frankly vitamin D deficient 
(<25 nmol/L) in pregnancy, although the value of treating relative vitamin D insufficiency in 
pregnancy is not clearly established. Women at risk of vitamin D deficiency should be monitored and 
treated during pregnancy for vitamin D deficiency [22]. 
7. Future Directions 
For maternal health outcomes in pregnancy and common offspring outcomes that can be measured 
at the fetal, perinatal or infant stage, randomized controlled trials are feasible. Such trials need to 
carefully consider the safety profile of the interventional vitamin D administration provided. Care is 
also needed at the trial design and implementation stages to reduce the possibility of potential 
contamination of the placebo or lower dose vitamin D group by additional subject-initiated vitamin D 
supplementation or increased UVR exposure. The randomized controlled trial design is the best design Nutrients  2009, 1                                       
 
 
399
to exclude that the range of possible health outcomes do not reflect other broad exposures such as 
lower socioeconomic status or nutritional deficiency. 
To examine the potential long term effects of low vitamin D on offspring health, randomized 
controlled trials studies may not be feasible, particularly for rare diseases with later onset such as 
schizophrenia. For these studies, observational studies will need to include seasonal variation in 
vitamin D status, potentially confounding by other seasonal factors such as infection, and also 
deseasonalized interpersonal variation in ingested vitamin D or UVR-derived vitamin D. With regard 
to these deaseasonalized markers of vitamin D status, it is highly likely that vitamin D status in 
pregnancy will be correlated with ingested or UVR-derived vitamin D exposure for mothers preceding 
pregnancy and offspring after pregnancy. In this situation, the timing of low vitamin D’s effect over 
the life course will have to be carefully determined, using specific life course analytic   
techniques [125], to assess whether any low prenatal vitamin D status is independently associated with 
health outcomes independently of the mother’s vitamin D status before pregnancy and the offspring’s 
vitamin D status during postnatal life. One advance that will assist this is the recent development of a 
sensitive liquid chromatography - tandem mass spectrometry assay of 25(OH)D that can be used for 
archived neonatal dried blood spots meaning that such samples will become a useful tissue repository 
for testing a range of hypotheses linking developmental hypovitaminosis D and adverse health 
outcomes in later life [126]. 
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